KYMR - CIK 0001815442
Kymera Therapeutics, Inc. (KYMR) reported net income of $311.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $311.35M | +39.1% |
| FY 2024 | $223.86M | +52.3% |
| FY 2023 | $146.96M | -5.1% |
| FY 2022 | $154.81M | +54.5% |
| FY 2021 | $100.22M | +319.8% |
| FY 2020 | -$45.59M | -10.5% |
| FY 2019 | -$41.25M | - |
Kymera Therapeutics, Inc. (KYMR) reported net income of $311.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Kymera Therapeutics, Inc.'s net income grew from -$41.25M to $311.35M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.